Sort
15,273 grants matching “antimicrobial resistance”
Discovering antimicrobials acting against MDR pathogens
$1,136,522Kim Lewis · Northeastern University · R01 · FY2022 · AI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,136,490David S Perlin · Hackensack University Medical Center · R01 · FY2020 · AI
Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative Bacteria
$1,135,599Ronald R Breaker · Yale University · R01 · FY2019 · AI
Structural characterization of OM proteins from Gram-negative pathogens
$1,134,246Susan Buchanan · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
CONTROL OF PERIODONTAL INFECTIONS
$1,130,207Forsyth Institute · P01 · FY2001 · DE
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa
$1,128,851David Elihu Greenberg · Ut Southwestern Medical Center · R01 · FY2020 · AI
Vaccine and Treatment Evaluation Units: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)
$1,127,342Mark Joseph Mulligan · Emory University · N01 · FY2019 · AI
Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia
$1,126,926Sophia Koo · Brigham And Women'S Hospital · R01 · FY2019 · AI
CAMPYLOBACTER IS A MAJOR FOODBORNE PATHOGEN AND A LEADING BACTERIAL CAUSE OF GASTROENTERITIS IN THE UNITED STATES AND OTHER COUNTRIES. CLINICAL TREATMENT OF CAMPYLOBACTERIOSIS REQUIRES THE USE OF FLUOROQUINOLONE (FQ) OR MACROLIDE ANTIBIOTICS, BUT ANTIBIOTIC-RESISTANT CAMPYLOBACTER IS INCREASINGLY PREVALENT, COMPROMISING THE EFFICACY OF CLINICAL TREATMENT. BECAUSE OF ITS SIGNIFICANCE TO PUBLIC HEALTH, CDC HAS RECENTLY IDENTIFIED DRUG-RESISTANT CAMPYLOBACTER AS A SERIOUS ANTIBIOTIC RESISTANCE THREAT IN THE U.S. CAMPYLOBACTER IS HIGHLY PREVALENT IN FOOD PRODUCING ANIMALS, AND RUMINANTS ARE IMPORTANT RESERVOIRS FOR THIS PATHOGENIC ORGANISM. RUMINANT CAMPYLOBACTER CAN BE TRANSMITTED TO HUMANS VIA CONTAMINATED MILK AND WATER, OR DIRECT CONTACT. ADDITIONALLY, RUMINANTS ARE AN IMPORTANT PART OF CAMPYLOBACTER ECOLOGY AND MAY SERVE AS A SOURCE OF CAMPYLOBACTER TRANSMISSION TO OTHER FARM ANIMALS, SUCH AS POULTRY. PREVIOUSLY, MOST EFFORTS ON ANTIBIOTIC-RESISTANT CAMPYLOBACTER WERE DEVOTED TO POULTRY, WHICH LED TO WITHDRAWAL OF FQ ANTIMICROBIALS FROM POULTRY PRODUCTION IN THE U.S. IN 2005. HOWEVER, NATIONAL SURVEILLANCE DATA INDICATE THAT FQ-RESISTANT CAMPYLOBACTER CONTINUES TO PERSIST AND EVEN SHOWS A RISING TREND AFTER FQ WITHDRAWAL IN POULTRY, SUGGESTING THAT ALTERNATIVE SOURCE(S) OF FQ-RESISTANT CAMPYLOBACTER MAY EXIST. OUR RECENT STUDY ON CAMPYLOBACTER ISOLATES FROM FEEDLOT CATTLE HERDS IN VARIOUS GEOGRAPHIC REGIONS REVEALED A SHARP INCREASE IN PROPORTIONS OF FQ-RESISTANT CAMPYLOBACTER IN CATTLE IN THE U.S. DURING THE PAST DECADE, WHICH COINCIDED WITH THE APPROVED USE OF FLUOROQUINOLONE ANTIMICROBIALS FOR CONTROL AND TREATMENT OF RESPIRATORY DISEASE IN CATTLE. TO REDUCE THE PREVALENCE OF FQ-RESISTANT CAMPYLOBACTER IN THE FOOD CHAIN, WE HAVE DEVELOPED A 3-YEAR INTEGRATED PROJECT TO IDENTIFY CRITICAL CONTROL POINTS FOR DEVELOPING MITIGATION STRATEGIES, DISSEMINATE SCIENCE-BASED KNOWLEDGE TO CATTLE PRODUCERS AND VETERINARIANS, AND TRAIN VETERINARY MEDICINE STUDENTS WITH HANDS-ON EXPERIENCE IN ANTIBIOTIC RESISTANCE RESEARCH. SPECIFICALLY, WE WILL 1) IDENTIFY CRITICAL CONTROL POINTS FOR MITIGATING THE DEVELOPMENT OF FQ-RESISTANT CAMPYLOBACTER IN CATTLE BY EVALUATING THE SELECTIVE PRESSURE IMPOSED BY DIFFERENT FQ TREATMENT REGIMENS, 2) UNDERSTAND THE EFFECT OF FQ TREATMENT ON GUT MICROBIOTA AND FQ RESISTANCE BY USING A METAGENOMICS APPROACH, AND 3) DEVELOP OUTREACH AND TRAINING PROGRAMS TO REDUCE FQ-RESISTANT CAMPYLOBACTER. THE PROPOSED WORK INVOLVES SIGNIFICANT PARTICIPATION BY STAKEHOLDERS AND DIRECTLY ADDRESSES MULTIPLE PRIORITY AREAS OF PROGRAM A4171 (EFFECTIVE MITIGATION STRATEGIES FOR ANTIMICROBIAL RESISTANCE). THE ACTIVITIES WILL YIELD IMPORTANT OUTCOMES THAT WILL REDUCE THE TRANSMISSION OF ANTIBIOTIC RESISTANT FOODBORNE PATHOGENS, IMPROVE FOOD SAFETY, AND ENHANCE THE SUSTAINABILITY OF THE U.S. CATTLE INDUSTRY.
$1,126,483Iowa State University Of Science And Technology · · FY2017 · National Institute of Food and Agriculture
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,125,966David S Perlin · Hackensack University Medical Center · R01 · FY2021 · AI
Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia
$1,125,660Sophia Koo · Brigham And Women'S Hospital · R01 · FY2022 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa
$1,125,531David Elihu Greenberg · Ut Southwestern Medical Center · R01 · FY2023 · AI
Biochemistry of Energy-Dependent (Intracellular) Protein Degradation
$1,124,895Michael Maurizi · Basic Sciences · Z01 · FY2007 · CA
Antimicrobial Oligomers for BioDefense and Emerging Food Borne Infectious Disease
$1,122,024Gregory N. Tew · University Of Massachusetts Amherst · U01 · FY2013 · AI
Atlas of efflux and permeation determinants to advance antibacterial therapeutic discovery
$1,120,070Helen I. Zgurskaya · University Of Oklahoma · R01 · FY2025 · AI
A Synthetic Platform for Non-Antibiotic Eradication of Bacterial Infections
$1,120,000Christophe Herman · Baylor College Of Medicine · DP1 · FY2023 · AI
A Synthetic Platform for Non-Antibiotic Eradication of Bacterial Infections
$1,120,000Christophe Herman · Baylor College Of Medicine · DP1 · FY2019 · AI
A Synthetic Platform for Non-Antibiotic Eradication of Bacterial Infections
$1,120,000Christophe Herman · Baylor College Of Medicine · DP1 · FY2020 · AI
A Synthetic Platform for Non-Antibiotic Eradication of Bacterial Infections
$1,120,000Christophe Herman · Baylor College Of Medicine · DP1 · FY2022 · AI
A Synthetic Platform for Non-Antibiotic Eradication of Bacterial Infections
$1,120,000Christophe Herman · Baylor College Of Medicine · DP1 · FY2021 · AI
Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs.
$1,119,996Manav Mehta · Gel4med, Inc. · R44 · FY2023 · DK
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea
$1,118,405Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · AI
Consortium for drug-resistant Gram-negative pathogen detection
$1,118,080Lee W Riley · University Of California Berkeley · R01 · FY2016 · AI
VACCINE AND TREATMENT EVALUATION UNITS: PHASE I TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS
$1,116,715Emmanuel B Walter · Duke University · N01 · FY2017 · AI
Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need
$1,116,150Chang Hee Kim · Godx, Inc. · R44 · FY2019 · TR